organ preservation

Revolutionizing Organ Preservation: An Ultra-low-cost, Open-source Normothermic Ex Vivo Perfusion Platform

By MedXY 10/31/2026

An innovative, ultra-low-cost normothermic machine perfusion (NMP) system was developed and validated, enabling extended organ preservation and in vivo function in porcine and human tissues, offering affordable platforms for research and therapeutic advancement.

Gastroenterology news Oncology

How the 2026 Chinese Consensus Changes Use of Immune Checkpoint Inhibitors in Locally Advanced Rectal Cancer

By MedXY 10/15/2026

The Chinese Society of Colorectal Surgery consensus (Gut 2026) standardizes use of immune checkpoint inhibitors (ICIs) in locally advanced rectal cancer—diagnostics, perioperative strategies, organ preservation, safety and follow-up.

Cardiology General Surgery news

Rapid Ultraoxygenated Recovery Eliminates the Need for Preimplant Reanimation in DCD Heart Transplants

By MedXY 02/09/2026

A JAMA study demonstrates that Rapid Ultraoxygenated Recovery (REUP) enables successful DCD heart transplantation without preimplant reanimation, achieving 96% survival despite extended ischemic times and older donors, potentially offering a more efficient, ethical alternative to current procurement strategies.

Gastroenterology news Oncology

Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial

By MedXY 11/29/2025

The NO-CUT phase 2 trial shows that total neoadjuvant therapy (CAPOX-based TNT) followed by non-operative management for clinical complete responders achieved high 30‑month distant relapse‑free survival (95%) and enabled organ preservation in 26% of patients with pMMR/MSS stage II–III rectal cancer.

Clinical Updates General Surgery Oncology Specialties

Advancing Organ Preservation in Locally Advanced Rectal Cancer: Insights from the CAO/ARO/AIO-16 Phase 2 Trial

By MedXY 08/14/2025

Total neoadjuvant therapy combined with watch-and-wait strategies achieves a 37% clinical complete response rate in locally advanced rectal cancer with manageable toxicity, offering an organ-preserving alternative to surgery.

Clinical Updates news Oncology Specialties

Expanding Nonoperative Management in Mismatch Repair–Deficient Early-Stage Solid Tumors: Phase 2 Evidence for Neoadjuvant PD-1 Blockade

By MedXY 08/01/2025

Neoadjuvant PD-1 blockade with dostarlimab enabled organ preservation and high recurrence-free survival in early-stage mismatch repair–deficient (dMMR) solid tumors, extending nonoperative management beyond rectal cancer.